anakinra-话题@MedSci

#anakinra#

4篇内容 | 1501人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2268699, encodeId=53fb226869966, content=<a href='/topic/show?id=ea86482116d' target=_blank style='color:#2F92EE;'>#巨细胞动脉炎#</a> <a href='/topic/show?id=e2f124e449' target=_blank style='color:#2F92EE;'>#anakinra#</a>, objectTitle=Arthritis Res Ther：Anakinra联合糖皮质激素治疗4个月未改善巨细胞动脉炎复发率和激素停用率, objectType=article, longId=881642, objectId=f9ba8816424e, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20250219/1739954389280_8538692.jpg, objectUrl=/article/show_article.do?id=f9ba8816424e, replyNumber=0, likeNumber=6, createdTime=2025-06-10, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=f9ba8816424e, moduleTitle=Arthritis Res Ther：Anakinra联合糖皮质激素治疗4个月未改善巨细胞动脉炎复发率和激素停用率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f9ba8816424e)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2118802, encodeId=013e211880250, content=<a href='/topic/show?id=e2f124e449' target=_blank style='color:#2F92EE;'>#anakinra#</a>用于<a href='/topic/show?id=f52851329b' target=_blank style='color:#2F92EE;'>#Covid-19#</a>相关继发性<a href='/topic/show?id=20cf105599ee' target=_blank style='color:#2F92EE;'>#噬血细胞淋巴组织细胞增多症#</a>, objectTitle=2020 NICE 证据总结：Anakinra用于COVID-19相关继发性噬血细胞淋巴组织细胞增多症【ES26】, objectType=guider, longId=22848, objectId=cae611c003020959, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/guideline/show_article.do?id=cae611c003020959, replyNumber=0, likeNumber=153, createdTime=2023-03-11, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=cae611c003020959, moduleTitle=2020 NICE 证据总结：Anakinra用于COVID-19相关继发性噬血细胞淋巴组织细胞增多症【ES26】, moduleType=guider, hrefUrl=https://www.medsci.cn/guideline/show_article.do?id=cae611c003020959)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517116, encodeId=279e151e1168b, content=<a href='/topic/show?id=e2f124e449' target=_blank style='color:#2F92EE;'>#anakinra#</a>, objectTitle=CHMP对 Kineret (anakinra) 治疗COVID-19持积极意见, objectType=article, longId=292250, objectId=43db292250ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43db292250ee, replyNumber=0, likeNumber=87, createdTime=2021-12-21, rootId=0, userName=12498e67m31暂无昵称, userId=7b0211025450, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43db292250ee, moduleTitle=CHMP对 Kineret (anakinra) 治疗COVID-19持积极意见, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=43db292250ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517115, encodeId=0536151e11582, content=<a href='/topic/show?id=e2f124e449' target=_blank style='color:#2F92EE;'>#anakinra#</a>, objectTitle=Lancet Rheumato：Anakinra治疗重症新冠肺炎患者, objectType=article, longId=195185, objectId=262d19518599, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=262d19518599, replyNumber=0, likeNumber=93, createdTime=2020-06-04, rootId=0, userName=12498e67m31暂无昵称, userId=7b0211025450, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=262d19518599, moduleTitle=Lancet Rheumato：Anakinra治疗重症新冠肺炎患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=262d19518599)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517114, encodeId=0fa1151e11437, content=<a href='/topic/show?id=e2f124e449' target=_blank style='color:#2F92EE;'>#anakinra#</a>, objectTitle=Kineret（anakinra）在英国批准用于罕见炎症性疾病的治疗, objectType=article, longId=144574, objectId=7bab1445e406, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7bab1445e406, replyNumber=0, likeNumber=97, createdTime=2018-07-18, rootId=0, userName=12498e67m31暂无昵称, userId=7b0211025450, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7bab1445e406, moduleTitle=Kineret（anakinra）在英国批准用于罕见炎症性疾病的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7bab1445e406)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

anakinra

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#巨细胞动脉炎# #anakinra#

Arthritis Res Ther：Anakinra联合糖皮质激素治疗4个月未改善巨细胞动脉炎复发率和激素停用率

2025-06-10发表于上海

侠胆医心 (审核中...)

前往app查看评论内容

#anakinra#用于#Covid-19#相关继发性#噬血细胞淋巴组织细胞增多症#

2020 NICE 证据总结：Anakinra用于COVID-19相关继发性噬血细胞淋巴组织细胞增多症【ES26】

2023-03-11发表于上海

12498e67m31暂无昵称 (审核中...)

前往app查看评论内容

#anakinra#

CHMP对 Kineret (anakinra) 治疗COVID-19持积极意见

2021-12-21

12498e67m31暂无昵称 (审核中...)

前往app查看评论内容

#anakinra#

Lancet Rheumato：Anakinra治疗重症新冠肺炎患者

2020-06-04

12498e67m31暂无昵称 (审核中...)

前往app查看评论内容

#anakinra#

Kineret（anakinra）在英国批准用于罕见炎症性疾病的治疗

2018-07-18

科室
- - 订阅+
  - 更多科室
工具
服务